🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 17 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/04/2009 6,54 6,60 4,98 5,88 -1,01% 24,77% 329.850
27/04/2009 7,26 7,74 5,70 5,94 +11,24% 28,10% 932.517
24/04/2009 4,38 5,58 4,38 5,34 +20,27% 27,40% 105.417
23/04/2009 4,26 4,44 4,14 4,44 +0,00% 7,04% 12.833
22/04/2009 4,62 4,62 4,38 4,44 -3,90% 5,19% 30.500
21/04/2009 4,20 4,62 4,02 4,62 +8,45% 14,29% 34.817
20/04/2009 4,26 4,32 4,14 4,26 +0,00% 4,23% 28.700
17/04/2009 4,02 4,32 4,02 4,26 +4,41% 7,46% 29.833
16/04/2009 4,32 4,32 4,02 4,08 -4,23% 6,94% 16.667
15/04/2009 4,20 4,32 4,02 4,26 +2,90% 7,14% 9.583
14/04/2009 4,26 4,32 4,02 4,14 +0,00% 7,04% 25.450
13/04/2009 4,20 4,26 4,14 4,14 +2,99% 2,86% 18.350
09/04/2009 4,20 4,32 3,96 4,02 -2,90% 8,57% 19.967
08/04/2009 4,08 4,14 3,96 4,14 +0,00% 4,41% 9.533
07/04/2009 4,26 4,32 4,08 4,14 -1,43% 5,63% 9.050
06/04/2009 4,08 4,32 4,08 4,20 +1,45% 5,88% 14.483
03/04/2009 4,26 4,32 4,08 4,14 -4,17% 5,63% 19.717
02/04/2009 4,26 4,62 4,26 4,32 +1,41% 8,45% 12.317
01/04/2009 4,02 4,62 4,02 4,26 +7,58% 14,93% 24.367
31/03/2009 4,74 4,80 3,96 3,96 -10,81% 17,72% 30.150
30/03/2009 4,68 4,68 4,26 4,44 -5,13% 8,97% 11.983
27/03/2009 4,74 4,92 4,50 4,68 +1,30% 8,86% 24.733
26/03/2009 4,50 4,62 4,44 4,62 +4,05% 4,00% 34.033
25/03/2009 4,14 4,62 4,14 4,44 +5,71% 11,59% 23.983
24/03/2009 4,74 4,74 4,14 4,20 -7,89% 12,66% 24.867
23/03/2009 4,80 4,92 4,56 4,56 +1,33% 7,50% 29.567
20/03/2009 4,68 4,98 4,50 4,50 -1,32% 10,26% 49.417
19/03/2009 4,50 4,68 4,38 4,56 +1,33% 6,67% 26.517
18/03/2009 4,50 4,74 4,38 4,50 +5,63% 8,00% 36.183
17/03/2009 3,96 4,44 3,96 4,26 +4,41% 12,12% 20.883